Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ILXO > ILEX Oncology > CURE for CANCER in 1999 -- Ignore unavailable to you. Want to Upgrade?

To: StockMiser who wrote (8)	7/20/1999 11:08:00 AM
From: StockMiser	Respond to of 23

A little bit about Covergence from the Yahoo boards... Claim anti-angiogensis molecules 10-100x better than ENMD's ----------- Anigiogenesis inhibitors act to inhibit new blood vessel formation and as such presents an exciting new therapeutic approach for cancer. The founders have pioneered studies in angiogenesis and sensitization of tumors by angiogenesis inhibition and believe, in a distinct break from competitors in the field, that the quickest route to regulatory approval will be in the area of tumor sensitization to specific pre-existing cancer therapies (i.e.,chemotherapy and radiation therapy) rather than as stand alone therapies themselves.The founders have identified and Convergence has licensed, at least four unique classes of novel, extracellular matrix-derived angiogenic inhibitors. Each family encompasses specific members which show >10-100 fold potency over the current leading angiogenesis inhibitor, endostatin. The Company's Arrestin, Restin, TumStatin and CanStatin show potent anti-tumor activity in a variety of malignant and resistant preclinical tumor models and may act via several independent mechanisms. Convergence controls proprietary yeast and E.coli production methods that are now already quite easily scalable to clinical production levels. Convergence expects to begin clinical testing within a year.There are several reasons why the Company's factors have developed such high pharmaceutical industry interest. These four families of natural products are unique since they very specifically block only endothelial cell growth. Moreover, the Convergence factors potently block blood vessel formation in response to a variety of growth factors. When competitively compared to all of the other anti-angiogenic factors being developed, only endostatin falls into this type of "pan specific" inhibitor class. However, its activity is very weak compared to the Convergence factors, and others find endostatin difficult to manufacture in an active form. Other anti-angiogenesis inhibitors such as VEGF antagonists only block one arm of a redundant tumor-derived endothelial growth pathway. Many tumors secrete bFGF for instance. Metalloprotease inhibitors have only marginal activities even in preclinical models. Other competitive agents such as anti-avb3 are likely to have significant toxicities since expression is not specific to tumor neovasculature. Since the Convergence factors are derived from naturally occurring basement membrane proteins, they are not likely to have toxicities at active doses, and indeed, none have been detected in animal models to date.

To: StockMiser who wrote (8)	7/20/1999 11:12:00 AM
From: StockMiser	Respond to of 23

Convergence is sold to firm Texas firm Hub company in $10m deal working on cancer drugs By Ronald Rosenberg, Globe Staff, 07/20/99 Convergence Pharmaceuticals Inc., formed four months ago by four researchers whose work includes some of the most promising recent developments in cancer treatment, was sold to Ilex Oncology Inc. for $10 million in Ilex stock yesterday. ''We were at the crossroads of raising venture capital money and looking at three companies wanting to acquire us, including Ilex,'' said Glenn Rice, chief executive of Boston-based Convergence. Interest in Convergence, which has 12 employees, has been centered on the research of its scientific founders, Dr. Vikas Sukhatme and Raghu Kalluri, who were developing compounds to starve cancerous tumors by shutting down blood vessel growth. Both are also researchers at Beth Israel Deaconess Medical Center and faculty members at Harvard Medical School. Just how cancer tumors establish a blood supply, a field known as angiogenesis, and figuring out how to shut down blood vessel growth, is a hot area of medical development. The pioneering angiogenesis work of Dr. Judah Folkman, a cancer researcher at Children's Hospital, drew worldwide headlines 14 months ago. Folkman has licensed two promising compounds to Convergence's main competitor, EntreMed Inc. of Rockville, Md. Sukhatme, a colleague of Folkman's at Harvard Medical School, was the first researcher to validate Folkman's key findings, which had been questioned by some medical researchers last year. Rice contends Convergence's drug candidates are more powerful and easier to make than Entremed's. The Ilex buy, he said, will enable Convergence to get its drugs into animal and human clinical trials much faster than if it had remained independent. Ilex is getting six compounds from Convergence, according to Richard Love, Ilex's president. Love said his four-year-old firm, based in San Antonio, has nine other cancer drugs in various stages of testing. Under the agreement, Convergence shareholders received 1 million Ilex shares, worth about $10 million based on Friday's closing price of 9 15/16. In addition, Convergence's founders, including Dr. Ralph Weichselbaum of the University of Chicago, and Dr. Donald Kufe, deputy director of the Dana-Farber Cancer Institute, can earn up to an additional 1 million Ilex shares if some of the proposed Convergence drugs reach certain clinical trial milestones, according to Rice and Love. Separately, Ilex is hoping to announce this summer a major pharmaceutical partner to market and distribute a promising leukemia-fighting drug called Campath. That drug aimed at an estimated 60,000 adult Americans was developed by LeukoSite Inc. of Cambridge and tested by Ilex under a joint venture announced in May 1997. Love said Ilex will file for US Food and Drug Administration approval of Campath later this year. Ilex shares closed at 9 29/32, down 1/32, on the Nasdaq exchange. This story ran on page D01 of the Boston Globe on 07/20/99.